Drug updated on 4/16/2024
| Dosage Form | Injection (intravenous: 500mg) |
| Drug Class | Lipoglycopeptide antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms.
Summary
- Dalbavancin (Dalvance) is indicated for treating acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive microorganisms, showing favorable efficacy against multi-drug-resistant organisms in various age groups, including newborns.
- Six systematic reviews/meta-analyses were analyzed regarding Dalbavancin's effectiveness, safety, and comparison with other antibiotics.
- In terms of treating ABSSSIs, Dalbavancin demonstrated similar clinical effectiveness to vancomycin and linezolid, with two doses of Dalbavancin showing a more favorable global microbiological assessment than a single dose, especially against methicillin-resistant and susceptible Staphylococcus aureus.
- Compared to commonly utilized antibiotics for Gram-positive bacteria infections, Dalbavancin displayed similar clinical responses but was superior in treating catheter-related bloodstream infections (CRBSIs) and osteomyelitis subgroups.
- A study revealed that Dalbavancin has a comparable safety profile, with fewer treatment emergent adverse effects reported than with other treatments. Specifically, lower mortality rates were observed compared to other antibiotic treatments, while the dual-dose regimen resulted in fewer adverse events, including reduced incidence of diarrhea.
- Dalbavancin exhibited potent activity against MRSA isolates, suggesting its strong antibacterial properties as an effective option for MRSA infection treatment. Furthermore, novel glycopeptides like Dalbavancin were associated with significantly fewer adverse events compared to vancomycin, indicating a better safety profile, particularly relevant given the high concern for nephrotoxicity common with vancomycin use.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Dalvance (dalbavancin) prescribing information. | 2021 | Allergan USA, Inc., Madison, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| New antimicrobials for the treatment of neonatal sepsis caused by multi-drug-resistant bacteria: A systematic review. | 2023 | Antibiotics |
| Acute bacterial skin and skin-structure infections, efficacy of dalbavancin: A systematic review and meta-analysis. | 2022 | Expert Review of Anti-infective Therapy |
| Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis. | 2022 | Annals of Clinical Microbiology and Antimicrobials |
| Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections. | 2021 | Journal Of Global Antimicrobial Resistance |
| Systematic review and meta-analysis on the safety of dalbavancin. | 2021 | Expert Opinion on Drug Safety |
| Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis. | 2021 | PLoS One |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: Expert review panel. | 2023 | International Journal of Antimicrobial Agents |
| 2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. | 2019 | Infectious Diseases Society of America |
| Cellulitis and erysipelas: Antimicrobial prescribing guideline | 2019 | NICE |